- Home
- PSHG vs ALLR Comparison
PSHG vs ALLR Comparison
Compare PSHG & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | ALLR |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 21.5M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSHG | ALLR |
|---|---|---|
| Price | $1.70 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 36.4K | ★ 69.6K |
| Earning Date | 05-26-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.77 |
| 52 Week High | $2.58 | $2.06 |
Technical Indicators
Market Signals| Indicator | PSHG | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a shipping company. The company is a provider of shipping transportation services through the ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying container vessels and cargo along various shipping routes. It owns and operates Aframax and Suezmax tanker vessels.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.